Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 8.2% – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price traded up 8.2% during mid-day trading on Wednesday . The company traded as high as $21.75 and last traded at $21.49. 91,333 shares traded hands during trading, a decline of 59% from the average session volume of 223,354 shares. The stock had previously closed at $19.86.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on DNTH shares. TD Cowen began coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating for the company. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday, November 11th. Finally, Oppenheimer boosted their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Dianthus Therapeutics has an average rating of “Buy” and a consensus price target of $46.83.

Dianthus Therapeutics Trading Up 2.2 %

The stock has a 50 day moving average price of $22.54 and a 200 day moving average price of $25.11. The company has a market capitalization of $711.22 million, a P/E ratio of -9.61 and a beta of 1.82.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Woodline Partners LP grew its holdings in Dianthus Therapeutics by 20.0% during the 4th quarter. Woodline Partners LP now owns 300,504 shares of the company’s stock worth $6,551,000 after acquiring an additional 50,000 shares during the last quarter. Vestal Point Capital LP grew its stake in shares of Dianthus Therapeutics by 172.2% in the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock worth $23,435,000 after purchasing an additional 680,000 shares during the last quarter. Octagon Capital Advisors LP increased its holdings in Dianthus Therapeutics by 20.8% in the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock valued at $46,002,000 after purchasing an additional 363,500 shares during the period. Millennium Management LLC raised its position in Dianthus Therapeutics by 160.2% during the 4th quarter. Millennium Management LLC now owns 90,436 shares of the company’s stock worth $1,972,000 after purchasing an additional 55,682 shares during the last quarter. Finally, Janus Henderson Group PLC raised its position in Dianthus Therapeutics by 14.4% during the 4th quarter. Janus Henderson Group PLC now owns 1,085,648 shares of the company’s stock worth $23,607,000 after purchasing an additional 136,314 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.